标题
Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights
作者
关键词
-
出版物
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
Volume -, Issue -, Pages 107424842093786
出版商
SAGE Publications
发表日期
2020-07-03
DOI
10.1177/1074248420937868
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
- (2020) Shiying Shao et al. PHARMACOLOGY & THERAPEUTICS
- Exposure to DPP ‐4 inhibitors and COVID ‐19 among people with type 2 diabetes. A case–control study
- (2020) Gian Paolo Fadini et al. DIABETES OBESITY & METABOLISM
- COVID-19 and diabetes: Can DPP4 inhibition play a role?
- (2020) Gianluca Iacobellis DIABETES RESEARCH AND CLINICAL PRACTICE
- COVID-19 and diabetes management: What should be considered?
- (2020) Antonio Ceriello et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- A NEW ERA FOR THE THERAPEUTIC MANAGEMENT OF THE ONGOING COVID-19 PANDEMIC
- (2020) ANDREEA LETIȚIA ARSENE FARMACIA
- Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
- (2020) Jing Yang et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
- (2020) Giacomo Grasselli et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management
- (2020) Anca Pantea Stoian et al. Metabolic Syndrome and Related Disorders
- Semaglutide as a promising antiobesity drug
- (2019) Georgios A. Christou et al. Obesity Reviews
- Liraglutide treatment reduced interleukin 6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy
- (2019) C. Brock et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
- (2019) Chen-Hsiu Lin et al. EXPERT OPINION ON PHARMACOTHERAPY
- GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
- (2018) Manfredi Rizzo et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice
- (2017) Kun Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials
- (2015) Wenjia Yang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
- (2014) Manfredi Rizzo et al. CURRENT PHARMACEUTICAL DESIGN
- Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
- (2009) Mark Kirby et al. CLINICAL SCIENCE
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
- (2009) Roger Yazbeck et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More